EA036660B1 - АНТИТЕЛО К Sp35 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ - Google Patents

Info

Publication number

EA036660B1

EA036660B1 EA201490693A EA201490693A EA036660B1 EA 036660 B1 EA036660 B1 EA 036660B1 EA 201490693 A EA201490693 A EA 201490693A EA 201490693 A EA201490693 A EA 201490693A EA 036660 B1 EA036660 B1 EA 036660B1

Authority

EA

Eurasian Patent Office

Prior art keywords

antibody

seq

antigen

human

binding fragment

Prior art date

2007-01-09

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 title claims abstract description 280
• 210000003169 central nervous system Anatomy 0.000 title claims abstract description 26
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 57
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 380
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 365
• 229920001184 polypeptide Polymers 0.000 claims abstract description 352
• 230000027455 binding Effects 0.000 claims abstract description 307
• 102000036639 antigens Human genes 0.000 claims abstract description 256
• 108091007433 antigens Proteins 0.000 claims abstract description 256
• 239000000427 antigen Substances 0.000 claims abstract description 255
• 241000282414 Homo sapiens Species 0.000 claims abstract description 246
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 148
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 148
• 239000002157 polynucleotide Substances 0.000 claims abstract description 147
• 239000013598 vector Substances 0.000 claims abstract description 53
• 230000006378 damage Effects 0.000 claims abstract description 34
• 208000020431 spinal cord injury Diseases 0.000 claims abstract description 27
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 22
• 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 16
• 206010012305 Demyelination Diseases 0.000 claims abstract description 16
• 206010067601 Dysmyelination Diseases 0.000 claims abstract description 14
• 208000003435 Optic Neuritis Diseases 0.000 claims abstract description 9
• 230000001154 acute effect Effects 0.000 claims abstract description 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 160
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 61
• 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 61
• 238000011282 treatment Methods 0.000 claims description 36
• 201000010099 disease Diseases 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 24
• 239000000203 mixture Substances 0.000 claims description 24
• 208000035475 disorder Diseases 0.000 claims description 22
• 210000001328 optic nerve Anatomy 0.000 claims description 21
• 238000002360 preparation method Methods 0.000 claims description 18
• 210000004556 brain Anatomy 0.000 claims description 16
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 102000005962 receptors Human genes 0.000 claims description 10
• 108020003175 receptors Proteins 0.000 claims description 10
• 102000007238 Transferrin Receptors Human genes 0.000 claims description 5
• 238000004113 cell culture Methods 0.000 claims description 5
• 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 4
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 4
• 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
• 208000006011 Stroke Diseases 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 102000047882 human INSR Human genes 0.000 claims description 2
• 238000007911 parenteral administration Methods 0.000 claims description 2
• 108010088365 B6 peptide Proteins 0.000 claims 1
• 102000004338 Transferrin Human genes 0.000 claims 1
• 108090000901 Transferrin Proteins 0.000 claims 1
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 1
• 229940125396 insulin Drugs 0.000 claims 1
• 239000012581 transferrin Substances 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 143
• 208000027418 Wounds and injury Diseases 0.000 abstract description 10
• 208000014674 injury Diseases 0.000 abstract description 10
• 208000029033 Spinal Cord disease Diseases 0.000 abstract description 5
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 abstract 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 abstract 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 abstract 1
• 208000015114 central nervous system disease Diseases 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 138
• 241000699666 Mus <mouse, genus> Species 0.000 description 125
• 108090000623 proteins and genes Proteins 0.000 description 113
• 235000001014 amino acid Nutrition 0.000 description 100
• 229940024606 amino acid Drugs 0.000 description 77
• 150000001413 amino acids Chemical class 0.000 description 75
• 210000004408 hybridoma Anatomy 0.000 description 69
• 150000007523 nucleic acids Chemical class 0.000 description 69
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 67
• 108060003951 Immunoglobulin Proteins 0.000 description 66
• 102000018358 immunoglobulin Human genes 0.000 description 66
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 61
• 102000039446 nucleic acids Human genes 0.000 description 61
• 108020004707 nucleic acids Proteins 0.000 description 61
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 58
• 102000004169 proteins and genes Human genes 0.000 description 55
• 235000018102 proteins Nutrition 0.000 description 51
• 108020004414 DNA Proteins 0.000 description 44
• 210000004248 oligodendroglia Anatomy 0.000 description 40
• 230000014509 gene expression Effects 0.000 description 38
• 210000002569 neuron Anatomy 0.000 description 35
• 238000006467 substitution reaction Methods 0.000 description 35
• 238000002965 ELISA Methods 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 28
• 241000700159 Rattus Species 0.000 description 27
• 239000012188 paraffin wax Substances 0.000 description 26
• 238000003364 immunohistochemistry Methods 0.000 description 25
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 24
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 24
• 230000023105 myelination Effects 0.000 description 24
• 239000013604 expression vector Substances 0.000 description 23
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 22
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 22
• 238000012217 deletion Methods 0.000 description 22
• 230000037430 deletion Effects 0.000 description 22
• 108020001507 fusion proteins Proteins 0.000 description 22
• 102000037865 fusion proteins Human genes 0.000 description 22
• 239000000047 product Substances 0.000 description 22
• 239000000463 material Substances 0.000 description 21
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 20
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 20
• 206010029240 Neuritis Diseases 0.000 description 20
• 108091028043 Nucleic acid sequence Proteins 0.000 description 20
• 238000005516 engineering process Methods 0.000 description 20
• 238000002823 phage display Methods 0.000 description 19
• 238000010494 dissociation reaction Methods 0.000 description 18
• 230000005593 dissociations Effects 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 18
• 210000001519 tissue Anatomy 0.000 description 18
• 230000000694 effects Effects 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 16
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 16
• 230000004048 modification Effects 0.000 description 16
• 238000012986 modification Methods 0.000 description 16
• 239000002773 nucleotide Substances 0.000 description 16
• 102000007079 Peptide Fragments Human genes 0.000 description 15
• 108010033276 Peptide Fragments Proteins 0.000 description 15
• 108010076504 Protein Sorting Signals Proteins 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 15
• 238000003501 co-culture Methods 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 239000013612 plasmid Substances 0.000 description 15
• 230000004069 differentiation Effects 0.000 description 14
• 238000001114 immunoprecipitation Methods 0.000 description 14
• 230000035772 mutation Effects 0.000 description 14
• -1 tripeptides Proteins 0.000 description 14
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 13
• 108091026890 Coding region Proteins 0.000 description 13
• 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 230000004927 fusion Effects 0.000 description 12
• 108020004999 messenger RNA Proteins 0.000 description 12
• DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 11
• 241001529936 Murinae Species 0.000 description 11
• 210000003050 axon Anatomy 0.000 description 11
• 229940072221 immunoglobulins Drugs 0.000 description 11
• 238000007912 intraperitoneal administration Methods 0.000 description 11
• 239000003550 marker Substances 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 102100027286 Fanconi anemia group C protein Human genes 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 102000006386 Myelin Proteins Human genes 0.000 description 10
• 108010083674 Myelin Proteins Proteins 0.000 description 10
• 241000283984 Rodentia Species 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 201000002491 encephalomyelitis Diseases 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 210000000020 growth cone Anatomy 0.000 description 10
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 210000005012 myelin Anatomy 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 9
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
• 239000004472 Lysine Substances 0.000 description 9
• 102000000343 Nogo Receptor 1 Human genes 0.000 description 9
• 108010041199 Nogo Receptor 1 Proteins 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 241000700605 Viruses Species 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 238000013518 transcription Methods 0.000 description 9
• 230000035897 transcription Effects 0.000 description 9
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 8
• 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 8
• 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 8
• 206010028980 Neoplasm Diseases 0.000 description 8
• 108700026244 Open Reading Frames Proteins 0.000 description 8
• 108020004511 Recombinant DNA Proteins 0.000 description 8
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
• 239000005557 antagonist Substances 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 8
• 238000003127 radioimmunoassay Methods 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 239000004475 Arginine Chemical group 0.000 description 7
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 7
• 241000894006 Bacteria Species 0.000 description 7
• 108010087819 Fc receptors Proteins 0.000 description 7
• 102000009109 Fc receptors Human genes 0.000 description 7
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 7
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
• 208000012902 Nervous system disease Diseases 0.000 description 7
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 7
• 229960001230 asparagine Drugs 0.000 description 7
• 235000009582 asparagine Nutrition 0.000 description 7
• 230000003376 axonal effect Effects 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 238000005755 formation reaction Methods 0.000 description 7
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
• 230000013595 glycosylation Effects 0.000 description 7
• 238000006206 glycosylation reaction Methods 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 239000003446 ligand Substances 0.000 description 7
• 230000000670 limiting effect Effects 0.000 description 7
• 230000004807 localization Effects 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 235000002639 sodium chloride Nutrition 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 229910052720 vanadium Inorganic materials 0.000 description 7
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 6
• 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 6
• 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 6
• 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 6
• 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 6
• 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 6
• 208000028226 Krabbe disease Diseases 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 230000021736 acetylation Effects 0.000 description 6
• 238000006640 acetylation reaction Methods 0.000 description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 238000002405 diagnostic procedure Methods 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 230000017066 negative regulation of growth Effects 0.000 description 6
• 201000001119 neuropathy Diseases 0.000 description 6
• 230000007823 neuropathy Effects 0.000 description 6
• 230000036961 partial effect Effects 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 208000033808 peripheral neuropathy Diseases 0.000 description 6
• 230000026731 phosphorylation Effects 0.000 description 6
• 238000006366 phosphorylation reaction Methods 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 238000012545 processing Methods 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 238000012546 transfer Methods 0.000 description 6
• 208000024827 Alzheimer disease Diseases 0.000 description 5
• 241000699802 Cricetulus griseus Species 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 5
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 5
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 210000003719 b-lymphocyte Anatomy 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 230000000302 ischemic effect Effects 0.000 description 5
• 238000013507 mapping Methods 0.000 description 5
• 201000000050 myeloid neoplasm Diseases 0.000 description 5
• 230000006576 neuronal survival Effects 0.000 description 5
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
• 230000001323 posttranslational effect Effects 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 4
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 4
• 208000011403 Alexander disease Diseases 0.000 description 4
• 208000023105 Huntington disease Diseases 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 208000025966 Neurological disease Diseases 0.000 description 4
• 102000010410 Nogo Proteins Human genes 0.000 description 4
• 108010077641 Nogo Proteins Proteins 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 239000004473 Threonine Substances 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 206010047631 Vitamin E deficiency Diseases 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 230000009435 amidation Effects 0.000 description 4
• 238000007112 amidation reaction Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 235000020958 biotin Nutrition 0.000 description 4
• 239000011616 biotin Substances 0.000 description 4
• 229960002685 biotin Drugs 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000002860 competitive effect Effects 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 238000000099 in vitro assay Methods 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 229960000310 isoleucine Drugs 0.000 description 4
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 230000014511 neuron projection development Effects 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 238000003259 recombinant expression Methods 0.000 description 4
• 239000004055 small Interfering RNA Substances 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• 239000004474 valine Substances 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 241000282836 Camelus dromedarius Species 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 3
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
• 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 3
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 238000010240 RT-PCR analysis Methods 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 201000011101 acute retrobulbar neuritis Diseases 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000003302 anti-idiotype Effects 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 238000001212 derivatisation Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 210000001671 embryonic stem cell Anatomy 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 230000022244 formylation Effects 0.000 description 3
• 238000006170 formylation reaction Methods 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 210000004901 leucine-rich repeat Anatomy 0.000 description 3
• 229910052751 metal Inorganic materials 0.000 description 3
• 239000002184 metal Substances 0.000 description 3
• 150000002739 metals Chemical class 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 230000007514 neuronal growth Effects 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 230000006320 pegylation Effects 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 230000009145 protein modification Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 208000022670 retrobulbar neuritis Diseases 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 210000003594 spinal ganglia Anatomy 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 230000009529 traumatic brain injury Effects 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• 108010022752 Acetylcholinesterase Proteins 0.000 description 2
• 102000012440 Acetylcholinesterase Human genes 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 235000014469 Bacillus subtilis Nutrition 0.000 description 2
• 208000006373 Bell palsy Diseases 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 241000283074 Equus asinus Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 241000724791 Filamentous phage Species 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 101000981680 Homo sapiens Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Proteins 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102100024102 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Human genes 0.000 description 2
• 241000721701 Lynx Species 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 241000235070 Saccharomyces Species 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 101150006914 TRP1 gene Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
• 241000700618 Vaccinia virus Species 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 229940022698 acetylcholinesterase Drugs 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 108010006025 bovine growth hormone Proteins 0.000 description 2
• 238000009395 breeding Methods 0.000 description 2
• 230000001488 breeding effect Effects 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 239000003593 chromogenic compound Substances 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 239000002619 cytotoxin Substances 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000003792 electrolyte Substances 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000011532 immunohistochemical staining Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 210000002241 neurite Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 229960003330 pentetic acid Drugs 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 239000002287 radioligand Substances 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000010473 stable expression Effects 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000014621 translational initiation Effects 0.000 description 2
• 208000009174 transverse myelitis Diseases 0.000 description 2
• 206010044652 trigeminal neuralgia Diseases 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• 101150094949 APRT gene Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
• 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 244000303258 Annona diversifolia Species 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 101100055634 Arabidopsis thaliana ANT gene Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 208000001827 Ataxia with vitamin E deficiency Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 241001112741 Bacillaceae Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102100035882 Catalase Human genes 0.000 description 1
• 108010053835 Catalase Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 235000005224 Eucalyptus bridgesiana Nutrition 0.000 description 1
• 244000239638 Eucalyptus bridgesiana Species 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101000844784 Homo sapiens Disks large-associated protein 1 Proteins 0.000 description 1
• 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• 102000009438 IgE Receptors Human genes 0.000 description 1
• 108010073816 IgE Receptors Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 102000004195 Isomerases Human genes 0.000 description 1
• 108090000769 Isomerases Proteins 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
• 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
• 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 101000933447 Mus musculus Beta-glucuronidase Proteins 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• 102000005781 Nogo Receptor Human genes 0.000 description 1
• 108020003872 Nogo receptor Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 241000709664 Picornaviridae Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 101000881112 Rattus norvegicus Dual specificity protein phosphatase 12 Proteins 0.000 description 1
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 102100040174 Testis-expressed protein 10 Human genes 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 101150008083 ant gene Proteins 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 230000028600 axonogenesis Effects 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 125000000837 carbohydrate group Chemical group 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 238000011210 chromatographic step Methods 0.000 description 1
• 230000009693 chronic damage Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• 108020001096 dihydrofolate reductase Proteins 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000003113 dilution method Methods 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000000635 electron micrograph Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 108010002591 epsilon receptor Proteins 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 201000003264 familial isolated deficiency of vitamin E Diseases 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• 150000003278 haem Chemical group 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000012606 in vitro cell culture Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 229940065638 intron a Drugs 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 150000002602 lanthanoids Chemical group 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000001459 mortal effect Effects 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 230000007498 myristoylation Effects 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
• 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 150000002482 oligosaccharides Polymers 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 210000001243 pseudopodia Anatomy 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 210000003994 retinal ganglion cell Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
• 108010038196 saccharide-binding proteins Proteins 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910052814 silicon oxide Inorganic materials 0.000 description 1
• 238000004088 simulation Methods 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 229940075554 sorbate Drugs 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000001296 transplacental effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 229940079023 tysabri Drugs 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 235000021119 whey protein Nutrition 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1